Vés al contingut

A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-finding Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects with Non-alcoholic Steatohepatitis (NASH) and Stage 3 or Stage 4 Liver Fibrosis

  • Codi protocol: CC-90001-NASH-001
  • Codi EudraCT: 2018-004431-79
  • Grup de recerca: Malalties Hepàtiques
  • Servei: Sense classificar
  • Investigador/a principal:  Pericàs Pulido, Juan Manuel
  • Fase: Fase II
  • Estat reclutament: Reclutant voluntaris